Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
received:
23
11
2023
accepted:
22
02
2024
revised:
20
02
2024
medline:
20
3
2024
pubmed:
20
3
2024
entrez:
20
3
2024
Statut:
aheadofprint
Résumé
Management of Richter transformation (RT) is particularly challenging, with survival estimates <1 year. We report on outcomes of 66 RT patients undergoing allogeneic-HCT (allo-HCT) between 2008 and 2018 registered with the EBMT. Median age at allo-HCT was 56.2 years (interquartile range (IQR), 51.3-63.1). Median time from RT to allo-HCT was 6.9 months (IQR, 4.9-11) and 28 (42.4%) were in complete remission (CR). The majority underwent reduced intensity conditioning (66.2%) using peripheral blood derived stem cells. Eighteen (27.3%) patients had a matched sibling donor, 24 (36.4%) a matched unrelated donor and the remaining were mismatched. Median follow-up was 6.6 years; 1- and 3- year overall and progression free survival (PFS) (95% CI) was 65% (54-77) and 39% (27-51) and 53% (41-65) and 29% (18-40), respectively. Patients in CR at time of allo-HCT had significantly better 3-year PFS (39% vs. 21%, p = 0.032). Cumulative incidences of grade II-IV acute graft versus host disease (GVHD) at day +100 was 41% (95% CI 29-53) and chronic GVHD at 3 years was 53% (95% CI 41-65). High rates of non-relapse mortality (NRM) were observed; 38% (95% CI, 26-50) at 3 years. Although potentially curative, approaches to reduce considerable NRM and chronic GVHD rates are required.
Identifiants
pubmed: 38503942
doi: 10.1038/s41409-024-02256-9
pii: 10.1038/s41409-024-02256-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014;123:1647–57.
doi: 10.1182/blood-2013-11-516229
pubmed: 24421328
pmcid: 3954047
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
doi: 10.1182/blood-2016-01-643569
pubmed: 26980727
pmcid: 4874220
Thompson PA, Siddiqi T. Treatment of Richter’s syndrome. Hematology. 2022;2022:329–36.
doi: 10.1182/hematology.2022000345
pubmed: 36485138
pmcid: 9820569
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. NEJM. 2015;373:2425–37.
doi: 10.1056/NEJMoa1509388
pubmed: 26639149
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. NEJM. 2014;371:213–23.
doi: 10.1056/NEJMoa1400376
pubmed: 24881631
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. NEJM. 2018;378:1107–20.
doi: 10.1056/NEJMoa1713976
pubmed: 29562156
Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. NEJM. 2014;370:2286–94.
doi: 10.1056/NEJMoa1400029
pubmed: 24869598
Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36:369–384.e13.
doi: 10.1016/j.ccell.2019.08.005
pubmed: 31543463
pmcid: 6801112
Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2018;9:342–53.
doi: 10.1158/2159-8290.CD-18-1119
pubmed: 30514704
Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023;29:158–69.
doi: 10.1038/s41591-022-02113-6
pubmed: 36624313
pmcid: 10155825
Ding W. Richter transformation in the era of novel agents. Hematology. 2018;2018:256–63.
doi: 10.1182/asheducation-2018.1.256
pubmed: 30504319
pmcid: 6245983
Croizier C, Guièze R. [Richter syndrome: diagnostic and therapeutic management]. Bull Cancer. 2021;108:521–7.
doi: 10.1016/j.bulcan.2021.01.014
pubmed: 33896586
Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M, et al. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nat Med. 2022;28:1662–71.
doi: 10.1038/s41591-022-01927-8
pubmed: 35953718
pmcid: 9388377
Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131:2761–72.
doi: 10.1182/blood-2018-01-791376
pubmed: 29692342
Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JCO. 2012;30:2211–7.
doi: 10.1200/JCO.2011.37.4108
Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, et al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021;5:3528–39.
doi: 10.1182/bloodadvances.2021004865
pubmed: 34496026
pmcid: 8945575
Kim HT, Baker PO, Parry E, Davids M, Alyea EP, Ho VT, et al. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter’s transformation. Haematologica. 2021;106:3219–22.
doi: 10.3324/haematol.2021.279033
pubmed: 34435483
pmcid: 8634179
Puckrin R, Owen C, Fontaine A, Peters A, Stewart D, Shafey M. Allogeneic hematopoietic cell transplantation for Richter transformation of chronic lymphocytic leukemia: an intention-to-transplant analysis. Bone Marrow Transpl. 2023;58:817–9.
doi: 10.1038/s41409-023-01978-6
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.
doi: 10.1016/j.bbmt.2009.07.004
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute gvhd international consortium. Biol Blood Marrow Transpl. 2016;22:4–10.
doi: 10.1016/j.bbmt.2015.09.001
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. BBMT. 2015;21:389–401.e1.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from Hl-A-matched sibling donors. Transplantation. 1974;18:295–304.
doi: 10.1097/00007890-197410000-00001
pubmed: 4153799
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO. 2014;32:3059–68.
doi: 10.1200/JCO.2013.54.8800
Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378–85.
doi: 10.1182/bloodadvances.2021005847
pubmed: 35143644
pmcid: 9198908
Tournilhac O, Dreger P Chronic Lymphocytic Leukaemia. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, éditeurs. The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022; http://www.ncbi.nlm.nih.gov/books/NBK584167/ .
Bensaber H, Bachy E, Beauvais D, Dulery R, Gastinne T, Villemagne B, et al. Anti-CD19 CAR T-Cell therapy for patients with Richter syndrome: a lysa study from the descar-T registry. Blood. 2022;140:3803–4.
doi: 10.1182/blood-2022-158807
Guieze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, et al. Blinatumomab for patients with Richter syndrome: final results of the phase 2 blinart trial from the filo group. Blood. 2022;140:6631–2.
doi: 10.1182/blood-2022-159695
Kater AP, Ye JC, Sandoval-Sus J, Bellido M, Christensen JH, Mato AR, et al. Subcutaneous epcoritamab in patients with Richter’s syndrome: early results from phase 1b/2 trial (EPCORE CLL-1). Blood. 2022;140:850–1.
doi: 10.1182/blood-2022-158298
Carlo-Stella C, Hutchings M, Offner F, Mulvihill E, Relf J, Byrne B, et al. Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter’s transformation. Hematol Oncol. 2023;41:63–5.
doi: 10.1002/hon.3163_28